Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7262 p197
16 August 2003

This article
Reprint
Photocopy


News summary


Anticoagulation self-testing to launch in Sheffield community pharmacies

A pilot project to move anticoagulation testing from secondary care to community pharmacies is about to start in Sheffield.

The project involves patients self-testing, but doing this in a pharmacy. The idea for the scheme came from Andrew Hartley, a community pharmacist in Sheffield who sits on both the local pharmaceutical committee and the professional executive committee of the primary care trust in south west Sheffield. “Secondary care has got a crisis with no capacity to deal with the growing number of people who need monitoring,” he told The Journal.

Patients will use CoaguChek S testing machines in community pharmacies to measure INR levels

The pilot will take place in five community pharmacies. Both pharmacists and pharmacy staff have been trained so that they can assist patients who are carrying out the tests. The pharmacies have been supplied with CoaguChek S machines and other material, such as laminated reminder cards to which patients can refer.

To participate, each pharmacy needs an area where a patient can sit and carry out a test. But Mr Hartley stresses that various approaches to this have been taken and it is not just for pharmacies that already had consultation areas. For example, one pharmacy has put a testing area into a back office that is separate from the dispensary.

When patients come for a test, they will be asked to fill in a form that contains some questions about recent illness and changes to medicines or supplements they are taking. The international normalised ratio (INR) test result will be added to this form and the pharmacist faxes a copy of it to the local surgery. The INR will also be recorded in the patient’s yellow book (INR record). Pharmacists also have to carry out quality assurance tests on the machine.

It is expected that each of the five pharmacies will see 50 patients a month during the pilot. These 250 patients account for 21 per cent of the total number of people requiring anticoagulation services in the area: this is about the figure by which secondary care services in Sheffield said they wanted their workload to be reduced. Looking to the future, Mr Hartley said that capacity could be increased if the pilot is rolled out. “The five sites could comfortably handle a couple of hundred patients each,” he said.

Pharmacists in the pilot will be paid a professional fee of £4 per patient for each test, and are also given an additional sum, of around £25 each month, to cover the costs of using the space in the pharmacy. “This project is extremely economic,” commented Mr Hartley.

Patients are currently being recruited to the pilot. Each of the pharmacies has links with a local surgery, and patients are being identified at these practices. A patient training session will be held in September where pharmacists and pharmacy staff, working with Roche (the manufacturer of the testing machine being used), will show patients how to self-test. In the longer term, it is hoped that as new patients join the scheme, they will be trained in the pharmacy.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal